PBYI
Puma Biotechnology, Inc. NASDAQ Listed Apr 24, 2012$7.56
+4.56%
vs $7.23
Mkt Cap $384.8M
52w Low $3.03
93.0% of range
52w High $7.90
50d MA $7.26
200d MA $6.13
P/E (TTM)
12.4x
EV/EBITDA
5.4x
P/B
2.9x
Debt/Equity
0.2x
ROE
23.9%
P/FCF
9.2x
RSI (14)
59.50
ATR (14)
$0.28
Beta
1.18
50d MA
$7.26
200d MA
$6.13
Avg Volume
245.3K
Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company's drug candidates include PB272 neratinib (oral) for the patients with early stage HER2-overexpressed/amplified breast cancer; PB272 (neratinib, oral) for the use of neratinib in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer; PB272 (neratinib, oral) for HER2 mutation-positive solid tumors. It has a license agreement with Pfizer, Inc.; and sub-license agreement with Specialised Therapeutics Asia Pte Ltd., CANbridge BIOMED Limited, Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.
10880 Wilshire Boulevard · Los Angeles, CA 90024 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 7, 2026 | AMC | -0.13 | -0.07 | +46.2% | 7.26 | -1.2% | +3.2% | -4.7% | -0.8% | +1.3% | +0.3% | — |
| Feb 26, 2026 | AMC | 0.24 | 0.29 | +20.8% | 7.60 | -17.1% | -25.0% | +12.6% | -3.3% | +3.1% | -2.7% | — |
| Nov 6, 2025 | AMC | 0.09 | 0.21 | +133.3% | 4.90 | +8.8% | +22.2% | -21.0% | +9.7% | -3.9% | -0.8% | — |
| Aug 7, 2025 | AMC | 0.11 | 0.15 | +36.4% | 3.29 | -7.3% | +12.2% | +31.4% | +0.4% | +8.8% | +0.4% | — |
| May 8, 2025 | AMC | 0.02 | 0.10 | +400.0% | 3.07 | +1.3% | -5.2% | +4.5% | -1.0% | -3.7% | +13.1% | — |
| Feb 27, 2025 | AMC | 0.10 | 0.43 | +330.0% | 2.99 | +3.3% | +19.7% | -6.4% | +1.2% | +4.4% | +2.3% | — |
| Nov 7, 2024 | AMC | 0.35 | 0.41 | +17.1% | 3.03 | +11.9% | -5.0% | +14.6% | -2.7% | -7.5% | +0.7% | — |
| Aug 1, 2024 | AMC | -0.10 | -0.05 | +50.0% | 3.50 | -6.3% | +9.4% | -6.3% | +12.3% | -7.4% | +2.7% | — |
| May 2, 2024 | AMC | -0.16 | -0.05 | +68.8% | 4.96 | +2.8% | -2.0% | -4.9% | +2.8% | +1.7% | -0.8% | — |
| Feb 29, 2024 | AMC | 0.30 | 0.26 | -13.3% | 6.22 | -14.0% | -5.3% | -9.0% | -3.4% | +6.8% | +4.0% | — |
| Nov 2, 2023 | AMC | 0.08 | 0.12 | +50.0% | 2.49 | -1.2% | +11.6% | +1.1% | +3.2% | +9.0% | +4.7% | — |
| Aug 3, 2023 | AMC | 0.07 | 0.10 | +42.9% | 3.52 | -4.0% | +8.5% | +3.1% | +3.8% | -0.2% | -1.2% | — |
| May 4, 2023 | AMC | 0.04 | 0.09 | +142.7% | 2.61 | +11.1% | +20.7% | +1.6% | -1.9% | -1.9% | -3.6% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 28 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.99 | $3.09 | +3.3% | +19.7% | -6.4% | +1.2% | +4.4% | +2.3% |
| Dec 23 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.75 | $2.77 | +0.7% | +2.2% | +7.5% | +4.3% | -2.2% | +1.6% |
| Nov 20 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.74 | $2.74 | +0.0% | +3.6% | +2.1% | +3.4% | +0.7% | +4.0% |
| Nov 8 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.03 | $3.39 | +11.9% | -5.0% | +14.6% | -2.7% | -7.5% | +0.7% |
| Aug 2 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.50 | $3.28 | -6.3% | +9.4% | -6.3% | +12.3% | -7.4% | +2.7% |
| Jul 26 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.94 | $3.99 | +1.3% | -2.8% | -5.7% | +0.3% | -0.8% | -2.5% |
| Jun 4 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.79 | $3.79 | +0.0% | -4.7% | +1.4% | -2.7% | -0.8% | -1.1% |
| Jun 3 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.85 | $3.91 | +1.6% | -1.6% | -4.7% | +1.4% | -2.7% | -0.8% |
| May 20 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.10 | $4.13 | +0.7% | +6.6% | -4.6% | +1.4% | -5.7% | +0.3% |
| May 3 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.96 | $5.10 | +2.8% | -2.0% | -4.9% | +2.8% | +1.7% | -0.8% |
| Mar 1 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $6.22 | $5.35 | -14.0% | -5.3% | -9.0% | -3.4% | +6.8% | +4.0% |
| Feb 13 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $6.36 | $6.34 | -0.3% | -2.4% | +19.2% | -5.5% | +1.7% | -4.5% |
| Sep 20 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.98 | $3.04 | +2.0% | -2.7% | +0.0% | -0.3% | -4.2% | -1.8% |
| Aug 4 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.52 | $3.38 | -4.0% | +8.5% | +3.1% | +3.8% | -0.2% | -1.2% |
| Jun 5 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.55 | $3.59 | +1.1% | +0.6% | -0.8% | +0.8% | -1.7% | -3.7% |
| May 5 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.61 | $2.90 | +11.1% | +20.7% | +1.6% | -1.9% | -1.9% | -3.6% |
| Mar 6 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.21 | $3.19 | -0.6% | -6.2% | -2.0% | -4.4% | -3.9% | -4.4% |
| Aug 31 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.75 | $2.80 | +1.8% | -2.5% | -2.2% | -1.5% | -4.3% | +0.8% |
| Aug 5 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.27 | $3.40 | +4.0% | +17.4% | -9.1% | +4.6% | -2.2% | -0.6% |
| May 6 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.24 | $2.39 | +6.7% | -11.2% | -15.6% | +8.3% | -9.9% | +6.7% |
| Sep 28 | Citigroup | Upgrade | Neutral → Buy | — | $7.12 | $7.64 | +7.3% | +2.5% | -3.7% | -0.3% | -7.7% | -3.1% |
| Aug 6 | RBC Capital | Maintains | Sector Perform → Sector Perform | — | $6.99 | $6.80 | -2.7% | +1.6% | -2.0% | +2.0% | +1.5% | +1.0% |
| Aug 6 | Goldman Sachs | Maintains | Sell → Sell | — | $6.99 | $6.80 | -2.7% | +1.6% | -2.0% | +2.0% | +1.5% | +1.0% |
| Aug 10 | Citigroup | Maintains | Neutral → Neutral | — | $10.27 | $10.12 | -1.5% | +2.6% | -4.8% | -1.1% | -0.1% | -0.8% |
| Aug 7 | SVB Leerink | Maintains | Market Perform → Market Perform | — | $10.38 | $10.38 | +0.0% | -1.1% | +2.6% | -4.8% | -1.1% | -0.1% |
| Jun 25 | BofA Securities | Maintains | Underperform → Underperform | — | $11.39 | $10.91 | -4.2% | -6.0% | -3.6% | -0.9% | +2.0% | +2.1% |
| May 20 | Cantor Fitzgerald | Maintains | Neutral → Neutral | — | $11.84 | $12.09 | +2.1% | +3.1% | -2.1% | -2.0% | -0.8% | -7.1% |
| Dec 6 | H.C. Wainwright | Maintains | Buy → Buy | — | $7.44 | $7.81 | +5.0% | +5.9% | -2.4% | +10.4% | +2.4% | +6.9% |
| Oct 8 | Goldman Sachs | Downgrade | Neutral → Sell | — | $10.07 | $8.88 | -11.8% | -21.9% | -2.7% | -5.2% | -1.7% | -4.9% |
| Aug 9 | Barclays | Maintains | Underweight → Underweight | — | $9.21 | $11.13 | +20.8% | +21.2% | -0.6% | -0.1% | -9.3% | -6.2% |
| May 10 | Citigroup | Downgrade | Buy → Neutral | — | $30.02 | $18.70 | -37.7% | -38.6% | -8.3% | +3.9% | -5.5% | +1.7% |
| May 10 | Cantor Fitzgerald | Downgrade | Overweight → Neutral | — | $30.02 | $18.70 | -37.7% | -38.6% | -8.3% | +3.9% | -5.5% | +1.7% |
| Mar 1 | Citigroup | Maintains | Buy → Buy | — | $27.81 | $36.85 | +32.5% | +40.0% | +3.0% | -3.6% | -5.1% | +4.1% |
| Jan 17 | Leerink Swann | Maintains | Market Perform → Perform | — | $25.33 | $25.11 | -0.9% | +0.6% | -1.0% | -6.1% | +3.7% | +6.7% |
| Jan 3 | Guggenheim | Downgrade | Buy → Neutral | — | $21.68 | $20.82 | -4.0% | -4.2% | +2.9% | +10.1% | +3.1% | -2.2% |
| Nov 19 | Goldman Sachs | Upgrade | Sell → Neutral | — | $23.58 | $24.19 | +2.6% | -2.1% | +0.2% | +1.9% | -1.3% | +1.3% |
| Nov 2 | JP Morgan | Maintains | Underweight → Underweight | — | $38.60 | $24.00 | -37.8% | -48.0% | +13.9% | -2.0% | +3.0% | +0.5% |
| Nov 2 | Barclays | Downgrade | Equal Weight → Underweight | — | $38.60 | $24.00 | -37.8% | -48.0% | +13.9% | -2.0% | +3.0% | +0.5% |
| Nov 2 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $38.60 | $24.00 | -37.8% | -48.0% | +13.9% | -2.0% | +3.0% | +0.5% |
| Oct 1 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $45.85 | $46.85 | +2.2% | +0.9% | +1.0% | -0.6% | -5.9% | +2.0% |
| Sep 18 | Citigroup | Maintains | Buy → Buy | — | $44.10 | $45.20 | +2.5% | +6.0% | +2.2% | -0.5% | -0.1% | -0.2% |
| Sep 17 | Goldman Sachs | Maintains | Sell → Sell | — | $47.00 | $45.55 | -3.1% | -6.2% | +6.0% | +2.2% | -0.5% | -0.1% |
| Aug 10 | JP Morgan | Maintains | Overweight → Overweight | — | $48.65 | $54.00 | +11.0% | -8.1% | -2.0% | +2.4% | -5.4% | +0.5% |
| Jun 28 | Citigroup | Maintains | Buy → Buy | — | $56.80 | $57.40 | +1.1% | -0.8% | +5.0% | +0.6% | -3.6% | +2.4% |
| Apr 12 | Barclays | Downgrade | Overweight → Equal Weight | — | $66.15 | $62.30 | -5.8% | +1.4% | -1.0% | -0.5% | +1.1% | -2.8% |
| Mar 9 | Stifel | Maintains | Buy → Buy | — | $80.85 | $82.45 | +2.0% | -0.1% | -1.6% | -7.1% | +0.6% | +0.2% |
| Mar 2 | Barclays | Maintains | Overweight → Overweight | — | $61.75 | $61.95 | +0.3% | +15.1% | +7.4% | -0.1% | +4.5% | +1.4% |
| Jan 24 | JP Morgan | Maintains | Overweight → Overweight | — | $90.90 | $66.95 | -26.3% | -28.8% | +5.3% | +0.9% | +0.3% | -4.6% |
| Jan 24 | Credit Suisse | Maintains | Outperform → Outperform | — | $90.90 | $66.95 | -26.3% | -28.8% | +5.3% | +0.9% | +0.3% | -4.6% |
| Jan 24 | Citigroup | Maintains | Buy → Buy | — | $90.90 | $66.95 | -26.3% | -28.8% | +5.3% | +0.9% | +0.3% | -4.6% |
| Date | Insider | Title | Type | Shares | Price | Value | Owned After | D1% | D5% |
|---|---|---|---|---|---|---|---|---|---|
| Jun 12, 2026 | Dorval AllisonDir | — | Sell | 11,610 | $7.20 | $84K | 90,780 | +1.41% | — |
| Jun 12, 2026 | MOYES JAY MDir | — | Sell | 22,000 | $7.22 | $159K | 58,322 | +1.41% | — |
| Jun 12, 2026 | Senderowicz AdrianDir | — | Sell | 27,000 | $7.20 | $194K | 27,000 | +1.41% | — |
| Jun 12, 2026 | Stuglik Brian MDir | — | Sell | 8,100 | $7.20 | $58K | 113,858 | +1.41% | — |
| Jun 12, 2026 | WILSON TROY EDWARDDir | — | Sell | 10,800 | $7.20 | $78K | 59,750 | +1.41% | — |
8-K
Puma Biotechnology, Inc. -- 8-K Filing
Jun 16
8-K
PUMA BIOTECHNOLOGY INC -- 8-K Filing
Puma Biotechnology reported its 2025 financial results, showing fourth-quarter and full-year performance for the biopharmaceutical company, providing investors insight into operational and commercial progress.
Feb 26
Institutional (13F) — Top 20
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Acadian Asset Management Llc | 2,041,759 | $13M | Added | Mar 2026 |
| 2 | Renaissance Technologies Llc | 1,942,413 | $12M | Reduced | Mar 2026 |
| 3 | Vanguard Capital Management Llc | 1,817,681 | $12M | New | Mar 2026 |
| 4 | Vanguard Portfolio Management Llc | 1,734,649 | $11M | New | Mar 2026 |
| 5 | Millennium Management | 1,477,519 | $9M | Added | Mar 2026 |
| 6 | Connor, Clark & Lunn Investment Management Ltd. | 875,301 | $5M | Reduced | Dec 2025 |
| 7 | Aqr Capital Management Llc | 800,194 | $5M | Added | Mar 2026 |
| 8 | Northern Trust Corp | 641,753 | $4M | Added | Mar 2026 |
| 9 | Morgan Stanley | 653,548 | $4M | Reduced | Dec 2025 |
| 10 | Arrowstreet Capital, Limited Partnership | 538,155 | $3M | Reduced | Mar 2026 |
| 11 | Ubs Group Ag | 534,227 | $3M | Added | Mar 2026 |
| 12 | Sei Investments Co | 508,182 | $3M | Added | Mar 2026 |
| 13 | D.e. Shaw & Co | 351,235 | $2M | Reduced | Mar 2026 |
| 14 | Bank Of New York Mellon Corp | 347,881 | $2M | Reduced | Mar 2026 |
| 15 | State Board Of Administration Of Florida Retirement System | 272,890 | $2M | Added | Mar 2026 |
| 16 | Prudential Financial Inc | 253,039 | $2M | Reduced | Mar 2026 |
| 17 | Russell Investments Group, Ltd. | 251,653 | $2M | — | Mar 2026 |
| 18 | Franklin Resources Inc | 215,391 | $1M | Added | Mar 2026 |
| 19 | Jpmorgan Chase & Co | 220,724 | $1M | Added | Mar 2026 |
| 20 | Panagora Asset Management Inc | 194,887 | $1M | — | Mar 2026 |
Mutual Funds / ETFs (N-PORT) — Top 20
All ↗
Valuation
Market Cap
$384.8M
Enterprise Value
$290.1M
P/E (TTM)
12.39x
Forward P/E
30.24x
PEG Ratio
0.00x
P/B
2.90x
P/S
1.68x
P/FCF
9.18x
EV/EBITDA
5.44x
Shares Out
50.7M
Financials (TTM)
Revenue
$228.4M
Net Income
$31.1M
EBITDA
$53.3M
Free Cash Flow
$41.7M
Op Cash Flow
$41.8M
EPS Basic
$0.62
EPS Diluted
$0.61
EPS Forward
$0.25
Gross Margin
74.5%
Op Margin
16.3%
Net Margin
13.6%
Balance Sheet
Total Assets
$216.3M
Total Liab.
$86.0M
Total Equity
$130.3M
Cash
$97.5M
LT Debt
$4.7M
Book Value/Sh
$2.61
Debt/Equity
0.22x
Current Ratio
2.00
Quick Ratio
1.93
Returns & Growth
ROE
23.9%
ROA
14.4%
ROIC
20.4%
Rev Growth YoY
-0.9%
EPS Growth YoY
—
Price Returns
2W
-0.3%
1M
-4.5%
3M
+25.8%
6M
+42.0%
12M
+118.6%
Technicals
52W High
$7.90
52W Low
$3.03
50d MA
$7.26
200d MA
$6.13
RSI (14)
59.50
ATR (14)
$0.28
Beta
1.18
Avg Volume
245K
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
—
High
—
Low
—
Median
—
Data updated apr 26, 2026 6:53pm
· Source: financialmodelingprep.com